Skip to main content

Table 1 Clinical characteristics of patients with GvHD

From: GVHD-derived plasma as a priming strategy of mesenchymal stem cells

GvHD classification

Sample

Age

Sex

Diagnosis

SCT source

GvHD affected organ/score

GvHD prophylaxis

Acute

GA1

14

M

AA

BM

Skin I

SIRO + MMF

GA2

10

F

ALL

BM

Skin III

SIRO + MMF

GA3

44

F

AA

BM

Eyes I/mouth I

GA4

30

F

B-ALL

BM

Mouth I/liver I

SIRO

GA5

19

M

ALL

BM

Skin/liverb

Prednisone

GA6

21

M

AA/PNH+

BM

Skin IV/liver/GIb

Prednisone + MMF

GA7

12

M

B-ALL

BM

Skin III

CSA

Chronic

GC1

26

M

BAL/MRD+

BM

Mild

GC2

36

M

CML

BM

Mild

GC3

52

F

AML

PBSC

CSA + prednisone

GC4

41

F

BAL/MRD+

PBSC

Moderate

CSA

GC5

50

F

CML

BM

CSA

GC6

43

M

CML

PBSC

Moderate

CSA + prednisone

GC7

12

M

ALL

BM

Mild

GC8

24

F

AML

PBSC

Mild

GC9

70

M

AML

BM

Mild

CSA

GC10

69

M

AML

BM

Severe

CSA

GC11a

61

M

Myelofibrosis

PBSC

Moderate

CSA + MMF

GC12

43

M

CML

PBSC

Severe

  1. M male, F female, AA aplastic anemia, ALL acute lymphoblastic leukemia, AML acute myeloblastic leukemia, BAL biphenotypic acute leukemia, BM bone marrow, CML chronic myeloid leukemia, CSA cyclosporine, MMF mycophenolate mofetil, MRD minimal residual disease, PBSC peripheral blood stem cells, PNH paroxymal nocturnal hemoglobinuria, SCT stem cell transplantation, SIRO sirolimus
  2. aOverlap syndrome
  3. bNon-classified